Fig 1: AEBP1 silencing sensitizes CAR cells to SSZ treatment in vivo. A-C. Tumor volume, tumor weight and body weight in sh-NC, sh-NC + cisplatin, sh-AEBP1 and sh-AEBP1 + cisplatin groups. **P < 0.01 versus sh-NC. #P < 0.05, ##P < 0.01 versus sh-NC + cisplatin. D-F Tumor volume, tumor weight and body weight in sh-NC, sh-NC + SSZ, sh-AEBP1 and sh-AEBP1 + SSZ groups. *P < 0.05, **P < 0.01 versus sh-NC. #P < 0.05, ##P < 0.01 versus sh-NC + SSZ
Fig 2: AEBP1 silencing inhibits cell proliferation, migration, and invasion of CAL27 cells. A The AEBP1 expression was detected by RT-qPCR in CAL27 cells. B Cell viability was measured by MTT assay in CAL27 cells. C The proliferation of CAL27 cells was detected by the EdU detection kit. D, E Cell migration and invasion were determined by transwell assay. **P < 0.01 versus sh-NC
Fig 3: Bioinformatics analysis of AEBP1 expression in GBM: (a) AEBP1 expression in GBM analyzed through the Xena database; (b, c) effect of AEBP1 expression on the overall survival of GBM patients analyzed through TCGA database.
Fig 4: Expression of AEBP1 in (a) GBM tissues and (b) cell lines. *P < 0.05.
Fig 5: Detection of adipocyte enhancer-binding protein 1 (AEBP1) upregulation in tumor endothelial cells (TECs). A, Workflow to isolate endothelial and epithelial cells from primary colorectal cancer (CRC) and corresponding normal colorectal tissues. B, Summary of RNA sequencing analysis to identify genes differentially expressed between normal endothelial cells and TECs. Genes upregulated in TECs are indicated in red. C, Relative expression of AEBP1 in endothelial cells (EPCAM-, CD146+) isolated from normal and CRC tissues. Expression levels are normalized to GAPDH expression. Error bars depict SEM. **P < .01. D, Immunohistochemical staining of CD31, CD146, and AEBP1 in representative primary CRC and adjacent normal tissues. Magnified views of the respective boxed areas are shown to the right. ANTXR1, anthrax toxin receptor 1
Supplier Page from Abcam for Anti-AE binding protein 1 antibody [EPR7733(2)]